Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia

Leukemia Research

Volumn 35, Issue 6, 2011, Pages 771-776

  Niu, Jihong ^a   Li, Henan ^b   Zhang, Yao ^a   Li, Jinlan ^a   Xie, Min ^a   Li, Lingdi ^a   Qin, Xiaoying ^a   Qin, Yazhen ^a   Guo, Xiaohuan ^b   Jiang, Qian ^a   Liu, Yanrong ^a   Chen, Shanshan ^a   Huang, Xiaojun ^a   Han, Wenling ^b   Ruan, Guorui ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; CMTM5; Methylation; Tumor suppressor gene

Indexed keywords

ACLARUBICIN; CKLF LIKE MARVEL TRANSMEMBRANE 5 PROTEIN; CYTARABINE; HOMOHARRINGTONINE; IDARUBICIN; MEMBRANE PROTEIN; RETINOIC ACID; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AML1 ETO GENE; ARTICLE; BCR ABL1 GENE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE FUSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; ONCOGENE; PML RARALPHA GENE; PRIORITY JOURNAL; PROMOTER METHYLATION; PROMOTER REGION; PROTEIN METHYLATION; TREATMENT RESPONSE; UPREGULATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; BONE MARROW CELLS; CELL LINE, TUMOR; CHEMOKINES; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA METHYLATION; DOWN-REGULATION; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; MALE; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; YOUNG ADULT;

EID: 79955573462     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.11.023     Document Type: Article

References (27)

1. Han W., Ding P., Xu M., et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics 2003, 81:609-617.
2. Han W., Lou Y., Tang J., et al. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J 2001, 357:127-135.
3. Shi S., Rui M., Han W., et al. CKLFSF2 is highly expressed in testis and can be secreted into the seminiferous tubules. Int J Biochem Cell Biol 2005, 37:1633-1640.
4. Zhong J., Wang Y., Qiu X., et al. Characterization and expression profile of CMTM3/CKLFSF3. J Biochem Mol Biol 2006, 39:537-545.
5. Shao L., Cui Y., Li H., et al. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res 2007, 13:5756-5762.
6. Jin C., Wang Y., Han W., et al. CMTM8 induces caspase-dependent and -independent apoptosis through a mitochondria-mediated pathway. J Cell Physiol 2007, 211:112-120.
7. Guo X., Li T., Wang Y., et al. CMTM5 induces apoptosis of pancreatic cancer cells and has synergistic effects with TNF-alpha. Biochem Biophys Res Commun 2009, 387:139-142.
8. Shao L., Guo X., Plate M., et al. CMTM5-v1 induces apoptosis in cervical carcinoma cells. Biochem Biophys Res Commun 2009, 379:866-871.
9. Wang Y., Li J., Cui Y., et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res 2009, 69:5194-5201.
10. Li H., Guo X., Shao L., et al. CMTM5-v1, a four-transmembrane protein, presents a secreted form released via a vesicle-mediated secretory pathway. BMB Rep 2010, 43:182-187.
11. Plate M., Li T., Wang Y., et al. Identification and characterization of CMTM4, a novel gene with inhibitory effects on HeLa cell growth through Inducing G2/M phase accumulation. Mol Cells 2010, 29:355-361.
12. Ma B.B., Sung F., Tao Q., et al. The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs 2010, 28:107-114.
13. Whitman S.P., Hackanson B., Liyanarachchi S., et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood 2008, 112:2013-2016.
14. Yu L., Liu C., Vandeusen J., et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 2005, 37:265-274.
15. Papaggeli P.C., Kortsaris A.C., Matsouka P.T. Aberrant methylation of c-myc and c-fos protooncogenes and p53 tumor suppressor gene in myelodysplastic syndromes and acute non-lymphocytic leukemia. J BUON 2003, 8:341-350.
16. Iravani M., Dhat R., Price C.M. Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia. Oncogene 1997, 15:2609-2614.
17. Beillard E., Pallisgaard N., van der Velden V.H., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003, 17:2474-2486.
18. Qin Y.Z., Liu Y.R., Zhu H.H., et al. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Int J Lab Hematol 2008, 30:317-323.
19. van der Velden V.H., Hochhaus A., Cazzaniga G., Szczepanski T., Gabert J., van Dongen J.J. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003, 17:1013-1034.
20. Licht J.D. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 2001, 20:5660-5679.
21. Stavroyianni N., Kalmantis T., Yataganas X. Simultaneous PML/RAR alpha and AML 1/ETO gene rearrangements in a patient with acute myeloid leukemia. Leukemia 1999, 13:1294-1295.
22. Virgili A., Brazma D., Reid A.G., et al. FISH mapping of Philadelphia negative BCR/ABL1 positive CML. Mol Cytogenet 2008, 1:14.
23. Frohling S., Scholl C., Gilliland D.G., Levine R.L. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005, 23:6285-6295.
24. Kantarjian H.M., Talpaz M., Giles F., O'Brien S., Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006, 145:913-923.
25. Das P.M., Singal R. DNA methylation and cancer. J Clin Oncol 2004, 22:4632-4642.
26. Blum W., Klisovic R.B., Hackanson B., et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007, 25:3884-3891.
27. Appleton K., Mackay H.J., Judson I., et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007, 25:4603-4609.